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Introduction: Worldwide, incidence and prevalence of multiple sclerosis (MS) have
increased over the last decades. We present a systematic epidemiological study with
recent prevalence and incidence rates of MS in Bavaria.
Methods: Incidence and prevalence of MS stratified by gender, age groups and region
were analyzed by data records from 2006 to 2015 of more than 10 million people insured
by the Bavarian Association of Statutory Health Insurance Physicians. Official statistics of
the German Federal Ministry of Health provided the size of the general population. Future
prevalence was estimated with a predictive model.
Results: From 2006 to 2015 prevalence of MS in Bavaria increased from 171 per
100,000 to 277 per 100,000, while incidence rates remained relatively stable (range
16–18 per 100,000 inhabitants with a female to male ratio between 2.4:1 and 2:1).
Incidence and prevalence were higher in urban than urbanized and rural areas. The
prevalence is expected to increase to 374 per 100,000 in 2040 with the highest
prevalence rates between 50 and 65 years.
Conclusion: The prevalence of MS in Bavaria is among the highest worldwide and
will further rise over the next two decades. This demonstrates a need to strengthen
healthcare provision systems due to the increasing numbers of particularly older patients
with MS in the future.
Keywords: multiple sclerosis, prevalence, incidence, regional distribution, Bavaria, Germany
INTRODUCTION
Multiple sclerosis (MS) is one of the leading causes for disability in young adults with a major
impact on quality of life of the affected persons (1, 2). Europe is a region with high prevalence
rates with half of the persons reported to be affected by MS in the world living in Europe (3, 4).
Population-based data from 1985 to 2011 suggest an increase of prevalence of MS worldwide with
an increase of the overall number of people with MS from 2.1 million in 2008 to 2.3 million in 2013
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according to the WHO (3–5). In population-based studies from
1985 to 2011, worldwide incidence rates of MS ranged from < 1
per 100,000 to > 10 per 100,000 (4, 6, 7). The prevalence and
incidence of MS is higher for women than men (ranging from
1.1:1 to 3:1 in the majority of European studies) (4). Over the last
decades, prevalence and incidence grew at a faster rate in women
than in men (4, 6–9).
In central Europe, including Switzerland, Germany, Austria
and Hungary, prevalence rates ranged from 62 per 100,000 to
128 per 100,000 with the lowest rates found in the 1990s in
Hungary and the highest prevalence rates analyzed in 2006 in
Germany (4).
From 2005 to 2009 an increase of prevalence from 102 per
100,000 to 143 per 100,000 in Germany was reported (10). At the
beginning of this century, the overall number of MS patients in
Germany was estimated with approximately 120,000 to 140,000
patients and a female to male ratio of 2.5:1 (11, 12). Recent
estimations of the health care provision system report about
an overall number of MS patients in Germany of 200,000 (13).
Reported incidence rates ranged from 4.6 per 100,000 in 1985 to
8.0 per 100,000 (14, 15). Due to the variety of data sources and
survey methods applied to different geographic populations, the
comparability of such results is inherently limited.
This project aimed to estimate the prevalence and incidence
of MS in the German federal state of Bavaria in the years of
2006–2015 together with their regional distribution. The study
comprises a systematic retrospective analysis of anonymous
claims data held by the Bavarian Association of Statutory Health
Insurance Physicians, covering about 85% of the population of
Bavaria.
METHODS
The incidence, prevalence and corresponding regional
distribution of MS in Bavaria were estimated on a yearly
basis from two different data sources. Ambulatory claims data
held by the Bavarian Association of Statutory Health Insurance
Physicians (BASHIP) were used to assess the number of MS
patients with a secured ICD-10 diagnosis G35. Study data,
aggregated by year gender and age group were extracted from a
pseudonymised database created by the BASHIP for the purpose
of health services research. Approval was obtained from the
responsible data protection officer of the BASHIP. Data covered
the years 2004 to 2016 and was stratified by region, gender
and the age groups [0, 15), [15, 20), [20, 25), . . . , [70, 110].
Here, the mathematical notation of intervals is used to indicate
inclusion by squared brackets “[” and “]”, and exclusion by round
brackets “(” and “)”. Therefore a patient transitions from the
interval [0, 15) to the interval [15, 20) on the 15th birthday, for
example. Estimates of incidence and prevalence have also been
standardized to the age distribution of the European standard
population (ESP) and the WHO standard population to support
comparability with data of other countries (16, 17).
A patient was considered to have MS if the secured ICD-
10 diagnosis G35 was present in at least two separate quarterly
periods, not necessarily in the same year. The year of diagnosis
was considered to be the year of incidence; a minimum period
of 2.5 years was available by which to exclude a previous MS
diagnosis. In subsequent years, the patient was only included
in the prevalence count if a corresponding MS diagnosis was
present. An MS diagnosis was assumed to be valid coded by a
neurologist at least once during the observation period.
The underlying population was taken from the official KM 6-
statistic of the German Federal Ministry of Health. This details
the number of statutorily insured persons in Bavaria by age
group and gender, but not by administrative district. The latter
was therefore inferred from the regional distribution of the
patient’s districts of residence as observed in the BASHIP claims
data.
Patients were also aggregated according to the regional
planning districts as defined by the German Federal Institute
for Research on building, urban affairs and spatial development,
each containing between 317,000 and 2.8 million residents and
classified using the categories urban, partially urbanized and
rural. In urban areas, 50% of the population live in cities
and the overall population density is >150 inhabitants per
km2. In rural areas, less than 50% of the population live in
cities and the population density outside the cities is <100
inhabitants per km2. Intermediate regions are classed as partially
urbanized.
Data were restricted to the years 2006 until 2015. In an
additional analysis, the prevalence for the period 2020–2040 was
forecast starting with the actual data for the year 2015. For each
discrete 5-year interval, the count of MS patients and the size of
the general population in 2015 were transitioned from one age
group to the next. At each step, several factors including the MS
incidence affect the group sizes either positively or negatively.
The mean values of the age specific incidence rates, which proved
to be rather stable within the years 2006–2015, were used for
this computation. Assuming a uniform distribution of age within
the age groups, each subject spends an average of 2.5 years
under the risk of two subsequent age groups considering a time
interval of 5 years. The corresponding incidence rates where
therefore each multiplied by a factor of 2.5 and applied to the
size of the general population of a given age group to add the
resulting expected count of new MS diagnoses in the transition
of this age group to the next age group for a step of 5 years.
In the same manner and taking the same effect, one-third of
the MS patients and the general population in age group [0, 15)
transitioned to the next age group. The size of the age group
[0, 15) was kept stable in this analysis, which assumes constant
birth rates. This stable amount of subjects not transitioning into
the next age group stayed under a stable risk estimated for this
age group [0, 15) for five years in each step. There was also no
transition of patients from the age group [70,110] to any older
age group and subjects stayed under the risk of this age group,
i.e., applying the corresponding incidence, for a period of 5 years
in each step. Taking a negative effect on the count of MS patients,
e.g., due to death, movements or any other cause, dropout rates
were computed for each age group and year from the BASHIP
claims data by identification of MS patients with terminating
records, i.e., patients without any claims records of any kind in
the years after a given year. These dropout rates were rather
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stable and were averaged across years for each age group and
gender. In the transition of MS patients from one age group to
the other, i.e., for a time shift of 5 years, the average dropout
rate of two subsequent age groups was applied five times to
resemble yearly dropout. Further losses and gains also had to be
expected for any cause, such as death and population movement,
in the general population. Annual dropout and accrual rates
between 2013 and 2014 stratified by age group and gender
were therefore estimated using the so-called “birth day sample”
(German: Geburtstagsstichprobe) of anonymous claims data that
has been augmented with a list of all insured persons and is
available from the german Institut des Bewertungsausschusses
(18). These rates were used to adjust the size of the general
population in the forecast as described for the dropout of MS
patients above. Concerning the oldest age group [70,110] it is
evident that dropout, most likely due to death, has to be taken
into account as otherwise, this group size would constantly rise
due to subjects transitioning into this age group with each step of
5 years taken in the forecast.
All computations were performed in R 3.4.2 (R Foundation
for Statistical Computing, Vienna, Austria).
RESULTS
General Aspects
Of the 12.8 million inhabitants of Bavaria in 2015, approximately
83.5% were covered by statutory health insurance plans (Federal
Statistical Office, 2015). Characteristics of the populations of
statutorily and privately insured persons can be inferred from
the 2015 microcensus results provided by the Federal Statistical
Office. Therefore the median age of statutorily and privately
insured persons was 46 and 48 years, with 52.3 and 41.5% women
and a median net income of 900–1300€ and 2000–2600€,
respectively. Gender is a well-known risk factor for MS and has
been taken into account in the following computations.
Prevalence
The overall prevalence of MS in Bavaria increased by 62%,
from 171 per 100,000 in 2006 to 277 per 100,000 in 2015
(Figure 1A, Table 1). The prevalence standardized to the age
distribution of the European standard population and the WHO
standard population are also given in Figure 1A and Table 1. In
2015, about 30,000 of 10,720,000 Bavarians enrolled in statutory
FIGURE 1 | (A) Prevalence of MS (overall, women, men and standardized to the age distribution) of the European standard population (ESP) and the WHO standard
population in Bavaria from 2006 to 2015 (increase of overall prevalence of MS by 62% from 171 per 100,000 in 2006 to 277 per 100,000 in 2015, increase of
prevalence of MS of men by 68% from 96 per 100,000 in 2006 to 160 per 100,000 in 2015, increase of prevalence of MS of women by 61% from 237 per 100,000 in
2006 to 382 per 100,000 in 2015). (B) Female to male ratio of prevalence of MS in Bavaria from 2006 to 2015 (decrease from 2.48 in 2006 to 2.38 in 2015).
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TABLE 1 | Overall Incidence and Prevalence of MS in Bavaria.
2006 2007 2008 2009 2010 2011 2012 2013 2014 2015
Women MS Cases 13,175 14,084 15,205 16,047 16,558 17,809 18,775 19,713 20,669 21,548
New Cases 1344 1,251 1,361 1,247 1,258 1,243 1,296 1,338 1,338 1,221
Population 5,552,393 5,555,248 5,559,404 5,553,047 5,542,847 5,541,188 5,554,480 5,574,694 5,613,912 5,645,713
Prevalence 237.29 253.53 273.5 288.98 298.73 321.39 338.02 353.62 368.17 381.67
Incidence 24.21 22.52 24.48 22.46 22.70 22.43 23.33 24.00 23.83 21.63
Men MS cases 4,624 4,957 5,387 5,673 5,919 6,452 6,885 7,341 7,724 8,138
New cases 499 445 536 480 512 524 539 582 548 543
Population 4,834,814 4,840,349 4,855,989 4,854,931 4,853,063 4,864,607 4,900,891 4,939,410 5,012,757 5,074,075
Prevalence 95.64 102.41 110.94 116.85 121.96 132.63 140.48 148.62 154.09 160.38
Incidence 10.32 9.19 11.04 9.89 10.55 10.77 11.00 11.78 10.93 10.70
Ratio (w:m) Prevalence 2.48 2.48 2.47 2.47 2.45 2.42 2.41 2.38 2.39 2.38
Incidence 2.35 2.45 2.22 2.27 2.15 2.08 2.12 2.04 2.18 2.02
Total MS Cases 17,799 19,041 20,592 21,720 22,477 24,261 25,660 27,054 28,393 29,686
New Cases 1,843 1,696 1,897 1,727 1,770 1,767 1,835 1,920 1,886 1,764
Population 10,387,207 10,395,597 10,415,393 10,407,978 10,395,910 10,405,795 10,455,371 10,514,104 10,626,669 10,719,788
Prevalence 171.36 183.16 197.71 208.69 216.21 233.15 245.42 257.31 267.19 276.93
Incidence 17.74 16.31 18.21 16.59 17.03 16.98 17.55 18.26 17.75 16.46
ESP* Prevalence 166.7 178.18 192.24 202.98 210.09 226.19 237.55 248.51 257.8 266.36
Incidence 17.14 15.85 17.66 16.19 16.67 16.56 17.2 17.91 17.38 15.98
WHO* Prevalence 149.87 159.66 171.79 180.67 186.74 199.65 208.48 217.24 224.62 230.8
Incidence 17.81 16.58 18.44 17 17.59 17.31 18.06 18.67 18.33 16.88
*Estimates standardized to the age distribution of the European standard population (ESP) and the WHO standard population.
health insurance plans were diagnosed with MS. Assuming a
similar prevalence across Germany, this would suggest that
approximately 230,000 persons were diagnosed with MS in 2015.
The prevalence in the male population increased by 68%, from
96 per 100,000 in 2006 to 160 per 100,000 in 2015 (Figure 1A,
Table 1). The prevalence in the female population increased by
61%, from 237 per 100,000 in 2006 to 382 per 100,000 in 2015
(Figure 1A, Table 1). Thus, the female to male ratio remained
largely unchanged during the observation period, equalling 2.48
in 2006 and 2.38 in 2015 (Figure 1B, Table 1).
The MS prevalence increased in all age groups (Figure 2A,
Table 2). Overall, the median age was not different in 2006 and
2015, varying between 40 and 45 years. Therefore, 50% of the
MS patients were at least 40 years. In both men and women, the
strongest increase in prevalence was observed in those aged 40–
60 years old. The median of the female to male ratios computed
within the age groups showed only little change during the
observation period, ranging from 2.49 in 2006 to 2.41 in 2015
(Figure 2B, Table 2). The female to male ratio was higher in
young adults (Figure 2B, Table 2).
Incidence
The incidence of MS was investigated in the same population.
Between 2006 and 2015 the incidence remained rather stable
(median 17.3, range 16.3 to 18.3 per 100,000 inhabitants,
Table 1). The incidence standardized to the age distribution
of the European standard population and the WHO standard
population are also given in this Table 1. Incidence was higher
among women (median 23.0, range 21.6–24.5 per 100,000) than
among men (median 10.7, range 9.2–11.8 per 100,000).
The highest incidence rates were found in persons aged 20–
50 years, with a peak incidence rate of 30.3 per 100,000 in men
aged 30–35 and 61.1 per 100,000 in women aged 25–30 (Table 2).
Incidence rates increased slightly in the age group 15–30 but
decreased slightly in older patients during the observation period.
Regional Distribution
The prevalence was higher in urban areas compared to partially
urbanized and rural areas. In 2015, the prevalence was 293
in urban, 287 in partially urbanized and 262 per 100,000 in
rural areas (Figure 3A). Between 2006 and 2015, the prevalence
increased in urban areas by 54%, in urbanized areas by 68% and
in rural areas by 64%. Incidence rates were higher in urban areas
as compared to partially urbanized or rural areas (Figure 3B).
FUTURE PREVALENCE RATES
The future prevalence rates in Bavaria were estimated as outlined
in the methods section. According to our predictive model, the
prevalence is set to reach 353 per 100,000 inhabitants by 2030
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FIGURE 2 | (A) Prevalence of MS in Bavaria (overall, women and men) correspondent to age groups (displayed in the gray bar on top of each graph) from 2006 to
2015. (B) Female to male ratio of prevalence of MS in Bavaria correspondent to age groups from 2006 to 2015.
and 374 per 100,000 inhabitants by 2040, with 50% of the MS
patients being older than 45 years in 2040 (Figure 4A). While
a small decrease in prevalence is expected in patients below the
age of 45, a sharp increase is expected among older people. In
2040, the highest prevalence will be observed in the people aged
between 50 and 65 years (Figure 4B).
DISCUSSION
Multiple sclerosis is one of the leading causes of disability in
young adults. Besides individual implications for the affected
people, the disease represents a significant socioeconomic burden
to society. We present the first authoritative data on the
prevalence and incidence of MS in Bavaria, one of the largest
states in Germany with more than 12 million inhabitants. We
observed a notable increase in the number of MS patients over
the last decade, with 18,000 Bavarians enrolled in public health
insurance plans being affected in 2006 and 30,000 in 2015. This
corresponds to a 62% increase in the overall prevalence, reaching
277MS patients per 100,000 Bavarians in 2015. Assuming the
same prevalence in Germany as a whole, this would suggest that
currently more than 230,000 Germans are diagnosed with MS.
As the prevalence among women increased at the same rate as
among men between 2006 and 2015, the female to male ratio
remained largely unchanged. There was no trend in the incidence
rates over the last decade, which ranged from 16 to 18 per 100,000
people. We observed a slightly higher prevalence and incidence
of MS in urban areas as compared to partially urbanized and
rural areas. According to our forecast, the prevalence of MS
will further increase at least until 2040, when we predict a
prevalence of almost 374 per 100,000 Bavarians, with more than
50% of MS patients being older than 45 years. Assuming a
similar trend across Germany, this would translate into more
than 300,000 Germans diagnosed with MS in 2040. A sharp
increase of prevalence is expected for people aged between 55
and 70 years while a small decrease in prevalence is expected in
patients below the age of 45.
Previous studies of prevalence and incidence have applied
different methodological approaches and can be affected
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TABLE 2 | Age dependent Incidence and Prevalence of MS in Bavaria.
Age_group 2006 2007 2008 2009 2010 2011 2012 2013 2014 2015
[0,15) MS cases 9 10 12 9 14 8 12 10 7 5
New cases 5 5 8 3 10 3 7 6 6 2
Population 1,533,054 1,500,539 1,472,703 1,443,013 1,413,975 1,387,482 136,6197 1,352,403 1,351,951 1,360,360
Prevalence 0.59 0.67 0.81 0.62 0.99 0.58 0.88 0.74 0.52 0.37
Incidence 0.33 0.33 0.54 0.21 0.71 0.22 0.51 0.44 0.44 0.15
[15,20) MS cases 119 113 142 160 165 168 165 154 171 151
New cases 45 48 55 66 60 66 57 58 66 49
Population 623,937 627,201 622,773 612,648 595,180 586,792 581,870 575,261 573,771 572,515
Prevalence 19.07 18.02 22.80 26.12 27.72 28.63 28.36 26.77 29.80 26.37
Incidence 7.21 7.65 8.83 10.77 10.08 11.25 9.80 10.08 11.50 8.56
[20,25) MS cases 525 525 572 592 620 636 663 727 760 776
New cases 154 142 166 159 184 155 162 173 193 180
Population 608,642 611,967 625,598 633,598 645,438 651,909 658,682 657,356 659,323 650,837
Prevalence 86.26 85.79 91.43 93.43 96.06 97.56 100.66 110.59 115.27 119.23
Incidence 25.30 23.20 26.53 25.09 28.51 23.78 24.59 26.32 29.27 27.66
[25,30) MS cases 1,127 1,242 1,362 1,394 1,424 1,500 1,499 1,587 1,626 1,738
New cases 236 238 281 237 259 276 287 283 275 299
Population 633,631 642,575 651,954 653,794 646,814 648,168 659,351 679,261 705,046 731,414
Prevalence 177.86 193.28 208.91 213.22 220.16 231.42 227.34 233.64 230.62 237.62
Incidence 37.25 37.04 43.10 36.25 40.04 42.58 43.53 41.66 39.00 40.88
[30,35) MS cases 1,703 1,755 1,833 1,912 1,982 2,141 2,328 2,442 2,580 2,616
New cases 261 241 234 237 232 225 285 293 281 266
Population 614,063 604,908 614,252 622,829 637,488 650,696 669,943 685,787 702,787 712,210
Prevalence 277.33 290.13 298.41 306.99 310.91 329.03 347.49 356.09 367.11 367.31
Incidence 42.50 39.84 38.10 38.05 36.39 34.58 42.54 42.72 39.98 37.35
[35,40) MS cases 2,526 2,579 2,669 2,631 2,599 2,581 2,621 2,749 2,894 3,051
New cases 315 269 282 251 244 209 230 268 271 223
Population 798,402 753,426 706,011 664,101 633,943 615,545 615,311 628,962 649,863 676,778
Prevalence 316.38 342.30 378.04 396.17 409.97 419.30 425.96 437.07 445.32 450.81
Incidence 39.45 35.70 39.94 37.80 38.49 33.95 37.38 42.61 41.70 32.95
[40,45) MS cases 3,150 3,301 3,373 3,514 3,506 3,639 3,654 3,580 3,562 3,522
New cases 329 257 298 283 240 272 239 238 230 210
Population 893,483 893,272 883,202 862,462 832,488 797,190 758,790 716,758 687,119 668,637
Prevalence 352.55 369.54 381.91 407.44 421.15 456.48 481.56 499.47 518.40 526.74
Incidence 36.82 28.77 33.74 32.81 28.83 34.12 31.50 33.21 33.47 31.41
[45,50) MS cases 2,652 2,948 3,401 3,641 3,786 4,104 4,334 4,379 4,504 4,522
New cases 200 231 258 209 238 226 234 218 236 206
Population 796,731 823,499 850,754 870,405 882,514 890,561 895,780 890,874 881,293 861,845
Prevalence 332.86 357.98 399.76 418.31 429.00 460.83 483.82 491.54 511.07 524.69
Incidence 25.10 28.05 30.33 24.01 26.97 25.38 26.12 24.47 26.78 23.90
(Continued)
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TABLE 2 | Continued
age_group 2006 2007 2008 2009 2010 2011 2012 2013 2014 2015
[50,55) MS cases 1,934 2,156 2,343 2,636 2,908 3,333 3,615 4,060 4,312 4,560
New cases 139 118 133 130 130 154 142 173 145 160
Population 663,667 681,315 705,433 732,961 763,466 794,711 823,634 853,777 880,535 898,352
Prevalence 291.41 316.45 332.14 359.64 380.89 419.40 438.91 475.53 489.70 507.60
Incidence 20.94 17.32 18.85 17.74 17.03 19.38 17.24 20.26 16.47 17.81
[55,60) MS cases 1,423 1,532 1,728 1,813 1,916 2,190 2,453 2,687 2,986 3,339
New cases 59 70 89 63 90 85 93 96 84 84
Population 618,679 627,952 632,366 636,199 640,150 654,434 672,654 698,240 730,463 763,296
Prevalence 230.01 243.97 273.26 284.97 299.30 334.64 364.67 384.82 408.78 437.44
Incidence 9.54 11.15 14.07 9.90 14.06 12.99 13.83 13.75 11.50 11.00
[60,65) MS cases 985 1,074 1,143 1,288 1,368 1,536 1,632 1,801 1,903 2,070
New cases 40 25 34 41 41 48 40 43 37 36
Population 519,345 524,174 529,933 542,222 580,978 597,700 606,367 610,917 616,057 621,266
Prevalence 189.66 204.89 215.69 237.54 235.47 256.99 269.14 294.80 308.90 333.19
Incidence 7.70 4.77 6.42 7.56 7.06 8.03 6.60 7.04 6.01 5.79
[65,70) MS cases 858 920 972 961 909 965 1,077 1,142 1,274 1,406
New cases 34 27 35 25 15 17 28 28 28 28
Population 673,449 654,293 625,791 584,910 521,565 489,285 493,699 499,743 511,731 547,514
Prevalence 127.40 140.61 155.32 164.30 174.28 197.23 218.15 228.52 248.96 256.80
Incidence 5.05 4.13 5.59 4.27 2.88 3.47 5.67 5.60 5.47 5.11
[70,100) MS cases 788 886 1,042 1,169 1,280 1,460 1,607 1,736 1,814 1,930
New cases 26 25 24 23 27 31 31 43 34 21
Population 1,410,124 1,450,476 1,494,623 1,548,836 1,601,911 1,641,322 165,3093 1,664,765 1,676,730 1,654,764
Prevalence 55.88 61.08 69.72 75.48 79.90 88.95 97.21 104.28 108.19 116.63
Incidence 1.84 1.72 1.61 1.48 1.69 1.89 1.88 2.58 2.03 1.27
by inaccuracy of diagnosis and data ascertainment with
subsequently restricted comparability. A study by Hoer A and
coworkers analyzed the prevalence of MS in Bavaria from 2005
to 2009 using the same ambulatory claims data combined with
prescribing data (10). The study took a different approach to
identifying MS patients, requiring either a single diagnosis from
a neurologist or psychiatrist or the collection of MS-specific
medication from a pharmacy (10). It found that MS prevalence
increased from 0.123 to 0.175%, which was then projected to
102,000 to 143,000 patients in the whole German population
(10). However, patient identification was based solely on a health
insurance number that was subject to change (e.g., marriage,
change of status or change of insurance company). The use
of a persistent patient identifier enables the present study to
observe patients reliably over the entire observation period,
improving estimation of prevalence and enabling the estimation
of incidence.
Another study evaluated nationwide Statutory Health
Insurance data covering both inpatient and outpatient services
in Germany for the year 2010 counting approximately 200,000
patients with MS diagnosis (13). An investigation by Hein
and coworkers used another approach with data based on
representative samples of groups of physicians engaged in MS
treatment, with the methodological risk of double counting and
without the possibility of questioning the diagnosis (12).
In the present study we performed a systematic retrospective
analysis of anonymous data held by the Bavarian Association
of Statutory Health Insurance Physicians covering 83.5% of the
Bavarian population between 2004 and 2016. In this respect
the data of MS incidence, prevalence and regional distribution
corresponded to a great majority of the Bavarian population.
The data represent the claims of outpatient health care providers
(outpatient clinics, general practitioners and registered medical
specialists) and contains broad and objective information related
to MS patients. The data include regional information, allowing
stratification not only by age group and gender, but also by
regional aspects. A minimum observation period of 2.5 years was
used to rule out any prior MS diagnoses. We provide evidence to
show that the prevalence in Bavaria is among the highest in the
world, reaching 277MS patients per 100,000 people in 2015.
Studies from other countries reported similar prevalence rates
such as Canada (240 per 100,000 in 2000/2001), Northern Ireland
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FIGURE 3 | (A) Regional distribution of prevalence of MS in Bavaria (urban, urbanized and rural areas) from 2006 to 2015 (prevalence of 293 in urban, of 287 in
urbanized and of 262 per 100,000 in rural areas in 2015, increase of prevalence from 2006 to 2015 in urban by 54%, urbanized by 68% and rural by 64%).
(B) Regional distribution of incidence of MS in Bavaria (urban, urbanized and rural areas) from 2006 to 2015.
(200.5 per 100,000 in 1996) and Scotland (between 203 and
219 per 100,000) (19–21). Older studies from central European
countries like Hungary (62–65 per 100,000 people at the end of
the 1990s), Austria (98.5 per 100,000 at the end of the 1990s) and
Switzerland (110 per 100,000 in 1986) reported lower prevalence
rates (22–25). We observed an increased prevalence over the past
decade similar to the results reported by studies from Denmark
(58.8 in 1950 to 154.5 per 100,000 in 2005) and Norway (19.3 in
1980 to 182.4 per 100,000 in 2010) (4, 26, 27).
Several investigations provide evidence for an increasing
incidence of MS (e.g., in northern Finland with an increase
especially in women from 1992 to 2007 and in the Nordland
County of Norway from 0.7 per 100,000 in 1970 to 1974 to 10.1
per 100,000 in 2005 to 2009) (27, 28). In our study, we found
that incidence rates were stable in Bavaria between 2006 and
2015. This is one of the surprising findings of our study with an
increase in prevalence despite stable incidence rates during the
observation period. This might be due to an increase in incidence
before the observation period, possibly caused by the broad
availability of magnetic resonance imaging and introduction of
new diagnostic criteria in 1983 and 2001 (29, 30). The access to
more and more effective immunotherapies may have improved
life expectancy of affected patients and thus have increased MS
prevalence despite stable incidence rates (4, 31).
Focusing on the female to male ratio of prevalence and
incidence ofMS, meta-analyses of studies over the previous 20-30
years provide evidence of a general but not ubiquitous increase
in the female to male ratio of incidence of MS possibly due to
changes in lifestyle, particularly among women (8, 32). In the
present study, the prevalence increased at the same rate in the
male and female populations between 2006 to 2015.
Looking at the regional distribution, our study found that
urban areas were associated with a higher prevalence than
partially urbanized and rural areas. Moreover, incidence rates
were higher in urban as compared to partially urbanized and
rural areas. These results are in line with data of studies
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FIGURE 4 | (A) Forecast of the future overall prevalence of MS in Bavaria (the prevalence of 277 per 100,000 inhabitants in 2015 is expected to increase to 353 per
100,000 inhabitants by 2030 and to 374 per 100,000 inhabitants by 2040). (B) Forecast of the future prevalence of MS correspondent to age groups in Bavaria.
Computational details are given in the methods section.
of Finland, Canada and South America that show regional
differences in MS prevalence and incidence (19, 32–34).
These differences might be explained by a better access of
patients to health care providers in urbanized and urban areas
including neurological doctor‘s offices as well as radiologists with
MRI scanners (19, 31–36). Also environmental factors might
contribute to regional differences (32–34, 37).
In this study, data on ethnic differences in the development
of MS prevalence and incidence rates in the last years was not
available but would be of great interest for future studies.
Our study has certain limitations. The diagnosis ofMS is based
on the assessment of individual Bavarian neurologists in private
practice. In this respect, the diagnostic MS criteria on which
clinicians based their diagnosis are unknown. Because physicians
in private practice are required to participate in continuing
education training and many activities for neurologists are
focused on MS, we assume a high standard of MS care in
private practice including knowledge on the current diagnostic
MS criteria.
Patients undiagnosed in the preliminary stages of the disease
and otherwise unreported cases are unaccounted for, possible
leading to an underestimation of the prevalence of MS in Bavaria.
Another reason for an underestimation of prevalence could be
incorrect coding by physicians. Most frequently, physicians used
non-specified MS diagnosis codes (ICD-10 code G35.9), hence
there is only partial information on the frequency of different
types and courses of MS in Bavaria. The study data encompassed
83.5% of the total Bavarian population (see Methods), limiting
generalizability to the population as a whole. Moreover, the
data do not cover the treatment of patients in hospitals or in
outpatient units of university hospitals. Furthermore another
diversification of the study might be a possible difference of the
Bavarian population compared to the overall German population
in respect to demographic characteristics. We counteracted this
fact by using age-group- and gender-specific measures for a
projection of the results onto the entire German population and
standardized our results to the age distribution of the European
standard population (ESP) and the WHO standard population.
Frontiers in Neurology | www.frontiersin.org 9 October 2018 | Volume 9 | Article 871
Daltrozzo et al. Prevalence of MS in Bavaria
However we cannot rule out further, unmeasured differences in
the demographic and regional structure.
In summary, our results on population based insurance data
depict a considerable increase of MS prevalence in Bavaria from
2006 to 2015. The rise of prevalence of MS demonstrates a need
to strengthen healthcare provision systems due to the increasing
numbers of particularly older patients with MS in the next
years. Future research should extend these data to the entirety
of Germany. Precise information about the distribution of MS in
Germany is necessary to inform the capacity planning of health
care services from an economic perspective as well as from the
perspective of those affected by MS.
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